Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose-escalation Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IMC-003 Injection in Patients With Pulmonary Arterial Hypertension (PAH) Receiving Background Therapy.

NCT07593027 is registered in ClinicalTrials.gov with ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. as lead sponsor.

NCT NCT07593027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07593027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multiple-dose, Dose-escalation Phase Ib/IIa Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of IMC-003 Injection in Patients With Pulmonary Arterial Hypertension (PAH) Receiving Background Therapy.
Lead sponsor
ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd.
Phase
Phase 1/2
Overall status
Recruiting
Start date
April 30, 2026
Completion date
November 30, 2027
Enrollment
120 (estimated)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

pulmonary arterial hypertension pah